1209 MontgomeryHighway • Birmingham, Alabama 35216-2809 • T E L (205) 978-5000 • FAX (205) 978-5005 • E-MAIL a s r m @ a s r m . o rg • URL w w w. a s r m . o rg PATIENT’S FACT SHEET
Insulin Sensitizing Agents and PCOS
Polycystic ovarian syndrome (PCOS) is a very common reproductive disorder. Women with PCOS frequently have irregular
menstrual cycles, excessive body hair, are overweight, and suffer from infertility. Many women with PCOS have a decreased
sensitivity to insulin for which their bodies compensate by overproducing insulin. The resulting high levels of insulin may
contribute to excessive production of androgens (male hormones, such as testosterone) and contribute to ovulation disorders.
In addition to reproductive problems, women with PCOS have a higher chance of developing medical problems such as Type
2 (non-insulin dependent) diabetes, high blood pressure, and heart disease. By the age of 40, up to 40% of PCOS patients
develop impaired glucose tolerance or clinical diabetes.
Given the strong evidence that excess insulin plays a role in the development of PCOS, it is reasonable to assume that reduc-ing circulating levels of insulin may help restore normal reproductive function. This may be accomplished by weight loss,improved nutrition, and exercise. These behavioral changes should be the first lines of therapy for an overweight woman withPCOS.
Recently, new drugs approved by the FDA for the treatment of Type 2 diabetes have shown promise for PCOS. These drugs,
known as insulin sensitizing agents, have been shown to improve the body’s response to insulin, thereby reducing the need
for excess insulin and restoring the levels to normal. The best studied insulin sensitizing agent available in the United States
for women with PCOS is metformin (Glucophage®), a biguanide. Metformin reduces circulating insulin and androgen levels
and restores normal ovulation in some women with PCOS. Even if metformin alone does not restore ovulation, it may
improve a woman’s response to fertility drugs. Gastrointestinal irritation, especially diarrhea, is a common side effect. These
symptoms usually improve after a few weeks. Lactic acidosis is a rare but serious adverse effect of metformin. Metformin is
not recommended for patients with kidney, lung, liver, or heart disease.
Rosiglitazone (Avandia™) and pioglitazone (Actos®), which belong to the thiazolidinedione group of antidiabetic agents, are
also available in the United States for women with PCOS. Thiazolidinediones have been shown to reduce hyperandrogenism
and restore ovulation in some PCOS patients. Liver toxicity is the main concern with these agents. Liver tests should be per-
formed every two months for the first year and periodically thereafter. These medications should not be started in women with
any evidence of liver disease.
So far, the new insulin sensitizing agents have not been linked to birth defects in animals or humans, but they are not recom-mended for use during pregnancy. Metformin should also be temporarily stopped prior to surgery or X-ray procedures that useintravenous contrast.
Unlike ovulation induction drugs, insulin sensitizing agents have little or no risk of multiple pregnancies. More clinical studiesare needed to determine the outcomes, risks, and complications when these medications are used to treat PCOS. Althoughresults from clinical studies have been encouraging, the use of these medications in women with PCOS is still consideredinvestigational. In general, Metformin is used as the first insulin sensitizing agent; thiazolidinediones may be considered ifmetformin is ineffective or not tolerated by the patient.
Present data suggest the use of insulin sensitizing agents for ovulation induction in PCOS patients who want to conceive.
Because these medicines correct the underlying metabolic abnormalities associated with PCOS, it is plausible that their long-term use may delay the emergence or reduce the likelihood of developing Type 2 diabetes and cardiovascular disease. Sincedata are lacking, h o w e v e r, long-term use of insulin sensitizing agents for this purpose cannot be recommended at present.
The American Society for Reproductive Medicine grants permission to photocopy this fact sheet and distribute it to patients.


Microsoft word - blogartikel 94.doc

Zyban om te stoppen met roken? Beste (ex-)roker, Ben je van plan om middels zyban te stoppen met roken? Goed, lees dit artikel dan zeerzeker aandachtig door, want het zal gegarandeerd een eye-opener voor je worden. Zyban is door de farmareus GlaxoSmithKline op de markt gebracht en wordt vandaag de dag veel gebruikt om succesvol te stoppen met roken. De een zegt dat hij succesvol is gesto

Psu blog - home - Professional Staff Union of the Ohio Education AssociationCopyright 2009 by the Professional Staff Union of OEA Dispelling theMyths…How MuchOEA’s Proposal WillCost YOUOEA President Pat Frost-Brooks, her fellow OEAOfficers Bill Leibensperger and Jim

Copyright © 2010 Find Medical Article